Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Lonza has finalized groundbreaking plans for the $300 million expansion of its Portsmouth, N.H., mammalian biopharmaceutical manufacturing facility. Expansion of this plant closely follows the start of construction of Lonza's second such facility at the end of last month in Singapore. In mid-May, the company will begin construction of the 330,000-sq-ft Portsmouth facility for biotherapeutics manufacturing technologies as well as offices, a warehouse, and support systems. At present, the total capacity at Portsmouth amounts to 93,000 L; the company is adding a 5,000-L bioreactor and expects to have that onstream in mid-2008, in addition to the new facility.
This article has been sent to the following recipient: